問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,704

    Total Beds

  • 806

    Total Doctors

  • ctc@ms.kmuh.org.tw
  • Yu-Sam Lin
  • 886-7-3121101#6643
  • 807Kaohsiung CityKaohsiung SanminNo.100, Tzyou 1st Rd., Sanmin Dist.,Sanmin,Kaohsiung City 807

Recruiting Trial

593Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1326Cases

2012-07-01 - 2015-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2012-05-01 - 2013-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2011-06-01 - 2013-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Study ended9Sites

2010-08-01 - 2020-07-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2017-08-01 - 2022-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated7Sites

2015-02-25 - 2025-12-31

Phase III

A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER

  • Test Drug

    MEDI4736

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting3Sites

Terminated8Sites

2022-06-01 - 2026-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2019-12-01 - 2022-12-31

Phase I

A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

  • Condition/Disease

    Solid Tumor/Non-Hodgkin's Lymphoma

  • Test Drug

    ATG-019

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2014-11-01 - 2019-03-31

Phase III

ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer

  • Condition/Disease

    Unresectable Advanced or Recurrent Gastric Cancer

  • Test Drug

    ONO-4538

Participate Sites
9Sites

Terminated9Sites

2014-03-01 - 2019-01-31

Phase III

A phase III, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

  • Condition/Disease

    hepatocellular carcinoma

  • Test Drug

    K-333

Participate Sites
17Sites

Terminated16Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

1 128 129 130 131 132 133
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB